

Review Form 1.6

| | |
|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| Journal Name: | Journal of Pharmaceutical Research International |
| Manuscript Number: | Ms_JPRI_80180 |
| Title of the Manuscript: | Determination of Platelets Parameters among Peoples Vaccinated with Oxford-AstraZeneca COVID-19 vaccines at Khartoum State -Sudan |
| Type of the Article | |

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalpri.com/index.php/JPRI/editorial-policy>)

PART 1: Review Comments

| | Reviewer's comment | Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here) |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Compulsory REVISION comments | <p>Please correct – “Oxford-AstraZeneca COVID-19 vaccines”. Instead of Oxford-AstraZeneca COVID-19 vaccines, writing 'Oxford-AstraZeneca COVID-19 vaccine' will be better.</p> <p>2. Please improve the sentences in the Abstract – Background: The global SARS-CoV-2 vaccination program has been hampered by several factors including the rare-and initially inexplicable emergence of vaccine-associated thrombosis, particularly venous territory strokes or other venous obstructions, including portal vein thrombosis, which has been dubbed Vaccine-Induced Thrombotic Thrombocytopenia (VITT).</p> | |
| Minor REVISION comments | Details of Reference No. 12 – missing. Should be added. | |
| Optional/General comments | The manuscript is advised to be published after the corrections. | |

PART 2:

| | Reviewer's comment | Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here) |
|-----------------------------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Are there ethical issues in this manuscript? | <i>(If yes, Kindly please write down the ethical issues here in details)</i> | |

Reviewer Details:

| | |
|----------------------------------|-------------------------------------------------------------|
| Name: | Vinod Nikhra |
| Department, University & Country | Hindu Rao Hospital & NDMC Medical College, India |